The presence of ALK point mutations, occurring in 8–10% of sporadic neuroblastoma, serve as biomarker of therapeutic sensitivity to small-molecule kinase inhibitors that are currently undergoing clinical assessment in phase I and II trials. The gene discussed is ALK; the disease is neuroblastoma.